In this provocative Viewpoint the authors challenge the concept that patients in clinical trials have a better survival and quality of life than those managed routinely. For instance, phase III trials of breast cancer that restrict access to post-study salvage chemotherapy have yielded 'superior' survival data for investigational drug combinations compared with single-agent therapy, despite poor survival in all cohorts. Should such studies set new standards of care for our patients?
- Siegfried Seeber
- Ada H Braun
